{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:42:16Z","timestamp":1773034936026,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41409-018-0161-1","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T11:30:04Z","timestamp":1523619004000},"page":"1304-1310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting"],"prefix":"10.1038","volume":"53","author":[{"given":"Alessandro","family":"Busca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Passera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Maffini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moreno","family":"Festuccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Brunello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara Maria","family":"Dellacasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Semra","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Frairia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Manetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Butera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Sorror","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9343-4099","authenticated-orcid":false,"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"161_CR1","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1086\/591969","volume":"47","author":"C Garcia-Vidal","year":"2008","unstructured":"Garcia-Vidal C, Upton A, Kirby KA, Mar KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47:1041\u201350.","journal-title":"Clin Infect Dis"},{"key":"161_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.bbmt.2014.03.004","volume":"20","author":"C Girmenia","year":"2014","unstructured":"Girmenia C, Raiola AM, Piciocchi A, Algarotti A, Stanzani M, Cudillo L, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20:872\u201380.","journal-title":"Biol Blood Marrow Transplant"},{"key":"161_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/tid.12328","volume":"17","author":"A Atalla","year":"2015","unstructured":"Atalla A, Garnica M, Maiolino A, Nucci M. Risk factors for invasive mold diseases in allogeneic hematopoietic cell transplant recipients. Transpl Infect Dis. 2015;17:7\u201313.","journal-title":"Transpl Infect Dis"},{"key":"161_CR4","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.bbmt.2015.03.018","volume":"21","author":"Y Sun","year":"2015","unstructured":"Sun Y, Meng F, Han M, Zhang X, Yu L, Huang H, et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study. Biol Blood Marrow Transplant. 2015;21:1117\u201326.","journal-title":"Biol Blood Marrow Transplant"},{"key":"161_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1600-0609.2011.01580.x","volume":"86","author":"PG Hemmati","year":"2011","unstructured":"Hemmati PG, Terwey TH, le Coutre P, Vuong LG, Massenkeil G, Dorken B, Arnold R. A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants. Eur J Haematol. 2011;86:305\u201316.","journal-title":"Eur J Haematol"},{"key":"161_CR6","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1002\/cncr.24531","volume":"115","author":"A Gratwohl","year":"2009","unstructured":"Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation. Cancer. 2009;115:4715\u201326.","journal-title":"Cancer"},{"key":"161_CR7","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123:3664\u201371.","journal-title":"Blood"},{"key":"161_CR8","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"161_CR9","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.bbmt.2015.04.002","volume":"21","author":"JE Vaughn","year":"2015","unstructured":"Vaughn JE, Storer BE, Armand P, Raimondi R, Gibson C, Rambaldi A, et al. Design and validation of an augmented hematopoietic cell transplantation-comorbidity index comprising pretransplant ferritin, albumin, and platelet count for prediction of outcomes after allogeneic transplantation. Biol Blood Marrow Transplant. 2015;21:1418\u201324.","journal-title":"Biol Blood Marrow Transplant"},{"key":"161_CR10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2012-03-414573","volume":"120","author":"R Raimondi","year":"2012","unstructured":"Raimondi R, Tosetto A, Oneto R, Cavazzina R, Rodeghiero F, Bacigalupo A, et al. Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study. Blood. 2012;120:1327\u201333.","journal-title":"Blood"},{"key":"161_CR11","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","volume":"32","author":"ML Sorror","year":"2014","unstructured":"Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249\u201356.","journal-title":"J Clin Oncol"},{"key":"161_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/blood-2014-01-550566","volume":"124","author":"ML Sorror","year":"2014","unstructured":"Sorror ML, Martin PJ, Storb RF, Bathia S, Maziarz RT, Pulsipher MA, et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood. 2014;124:287\u201395.","journal-title":"Blood"},{"key":"161_CR13","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","volume":"98","author":"L Luznik","year":"2001","unstructured":"Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex\u2013incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456\u201364.","journal-title":"Blood"},{"key":"161_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295\u2013304.","journal-title":"Transplantation"},{"key":"161_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1182\/blood.V100.2.406","volume":"100","author":"SJ Lee","year":"2002","unstructured":"Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100:406\u201314.","journal-title":"Blood"},{"key":"161_CR16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"key":"161_CR17","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B Pauw De","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813\u201321.","journal-title":"Clin Infect Dis"},{"key":"161_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J. 1958;53:457\u201381.","journal-title":"Am Stat Assoc J"},{"key":"161_CR19","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141\u201354.","journal-title":"Ann Stat"},{"key":"161_CR20","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","volume":"110","author":"ML Sorror","year":"2007","unstructured":"Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shajahan M, Maloney DG, et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110:4606\u201313.","journal-title":"Blood"},{"key":"161_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bbmt.2013.10.011","volume":"20","author":"P Barba","year":"2014","unstructured":"Barba P, Martino R, P\u00e9rez-Sim\u00f3n JA, Fernandez-Aviles F, Castillo N, Pinana JL, et al. Combination of the hematopoietic cell transplantation comorbidity index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:66\u201372.","journal-title":"Biol Blood Marrow Transplant"},{"key":"161_CR22","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.bbmt.2015.04.004","volume":"21","author":"ML Sorror","year":"2015","unstructured":"Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21:1479\u201387.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"161_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jmii.2015.01.002","volume":"49","author":"Yao-Chung Liu","year":"2016","unstructured":"Liu Y-C, Chien S-H, Fan N-W, Hu M-H, Gau J-P, Liu C-J, et al. Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation. J Microbiol Immunol Infect. 2015;49:567\u2013574.","journal-title":"Journal of Microbiology, Immunology and Infection"},{"key":"161_CR24","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/j.1469-0691.2009.03015.x","volume":"16","author":"J Guinea","year":"2010","unstructured":"Guinea J, Torres-Narbona M, Gijo\u00b4 P, Munoz P, Pozo F, Pelaez T, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect. 2010;16:870\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"161_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2014.113399","volume":"100","author":"M Caira","year":"2015","unstructured":"Caira M, Candoni A, Verga L, Busca A, Delia M, Nosari A, et al. Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica. 2015;100:284\u201392.","journal-title":"Haematologica"},{"key":"161_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/bmt.2014.229","volume":"50","author":"R Parody","year":"2015","unstructured":"Parody R, Martino R, de la C\u00e1mara R, Garcia-Noblejas A, Esquirol A, Garcia-Cadenas I, et al. Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time. Bone Marrow Transplant. 2015;50:274\u201381.","journal-title":"Bone Marrow Transplant"},{"key":"161_CR27","doi-asserted-by":"publisher","first-page":"e75531","DOI":"10.1371\/journal.pone.0075531","volume":"8","author":"M Stanzani","year":"2013","unstructured":"Stanzani M, Lewis RE, Fiacchini M, Ricci P, Tumietto F, Viale P, et al. A risk prediction score for invasive mold disease in patients with hematological malignancies. PLoS ONE. 2013;8:e75531.","journal-title":"PLoS ONE"},{"key":"161_CR28","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00277-014-2108-y","volume":"93","author":"D Tacke","year":"2014","unstructured":"Tacke D, Buchheidt D, Karthaus M, et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Ann Hematol. 2014;93:1449\u201356.","journal-title":"Ann Hematol"},{"key":"161_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/cid\/ciw444","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:433\u201342.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"161_CR30","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/bmt.2010.177","volume":"46","author":"R Martino","year":"2010","unstructured":"Martino R, Kerguelen A, Valcarcel D, Sureda A, Fachini L, Pinana JL, et al. Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. Bone Marrow Transplant. 2010;46:690\u2013701.","journal-title":"Bone Marrow Transplantation"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0161-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:11:51Z","timestamp":1684617111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0161-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["161"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0161-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,13]]},"assertion":[{"value":"19 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AB has received honoraria from Gilead Sciences, Merck, Pfizer Pharmaceuticals, Jazz Pharmaceuticals, and Basilea; he has been the speaker for Gilead Sciences, Merck, Pfizer Pharmaceuticals, Astellas Pharma, and Basilea. BB has received honoraria from Gilead, Pfizer, Celgene, Hospira, and research support form Celgene, Pierre Fabre, ADIENNE, Hospira Italia, MSD Italia. The The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the present study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}